Needless to say, every investor is looking for big returns, and while there are multiple paths to trying to achieve that goal, following the moves of Wall Street’s most successful investors can be difficult. Definitely a good starting point.
One investor pretty close to the top is Izzy Englander. Interested in the stock market from an early age, Englander traded stocks in high school. By 1989, he founded the hedge fund Millennium Management with $35 million in initial funds, which by the end of last year had managed $57.5 billion in assets. So it was natural that when Englander pulled out his checkbook, investors wanted to peek inside his shopping bag.
With this in mind, we’ve gathered insights into the investment giant’s three recent purchases and rounded them up. TipRanks database to see what the Street experts have to say about their picks. As it turned out, they were all rated as Strong Buy by consensus of analysts. Find out why they ticked all the boxes now.
Forestry Oil Joint Stock Company (ROCC)
The first British-backed stock we’ll look at is an independent oil and gas company, Ranger Oil Corporation. The company specializes in the development and production of crude oil, liquid natural gas and onshore natural gas. Ranger’s primary operations take place in Eagle Ford Shale, South Texas, where the company’s operations include drilling unique horizontal development wells and operating production wells.
From the company’s latest set of quarterly results, it’s clear that Ranger enjoyed an oil and natural gas boom in 2022. In the third quarter, Ranger generated 305.09 sales. million dollars, a year-over-year growth of 117.7% and far exceeding Street’s expectations of $40.09 million. It’s a similar story at the bottom line, with EPS of $5.26 being a long way from the $3.13 analysts had predicted.
Energy stocks have performed very well in 2022, completely outperforming the bear, and Ranger is no different. Stocks are up 31% year-to-date, though Englander still has to believe they offer excellent value. He opened a new position in Q3 by buying 692,054 shares, now worth more than $24 million.
He’s not the only one who sees value here. Scan the Q3 print and assess its outlook, analyst Truist Neil Dingmann think the company is making all the right moves.
“Ranger continues to use the right leverages to position the company for record 2023 output/earnings/FCF relative to many other E&Ps who will see results slide,” said 5-star analyst. write. “Most recently, the company added a third rig and benefited significantly from pads to be drilled soon, both of which helped drive absolute production growth. We expect ROCC to prudently use its potential future FCF to scale up its business and deliver shareholder returns (specifically, share buybacks) whichever is chosen. offers the highest short-term returns.”
Unsurprisingly, Dingmann gives ROCC a Buy rating while his $57 price target offers a chance for a 12-month return of 61%. (To see Dingmann’s achievements, click here)
Now turning to the rest of the Street, other analysts echo Dingmann’s view. 3 Buy and no Hold or Sell combined will form a Strong Buy consensus rating. Going by the average target of $55, the stock should go ~56% higher in a one-year time frame. (View ROCC stock forecast on TipRanks)
Dolby Lab (DLB)
Famous for inventing the Dolby Noise Reduction system, Ray Dolby founded Dolby Laboratories in London, England in 1965. Based in the United States since the mid-70s, the company has been a pioneer and Sound innovation with technology like acoustic noise reduction. , spatial audio, HDR video and audio encoding/compression are essentially considered industry standards and all provide consumers with digital content – songs, video games, movies – with a richer experience. The company earns almost all of its revenue by licensing customers to use its proprietary patents for which it collects royalties.
However, like many others, 2022 will not be easy, which was evident in the company’s recent Q4 financial report. Revenue fell 2.4% year-over-year to $278.2 million, below the consensus estimate of $27.03 million. Adjective. EPS also fell short of expectations, at $0.54, below expectations of $0.71.
The outlook is also not worth mentioning. For the first fiscal quarter, the company expects revenue between $300 million and $330 million and EPS between $0.46 and $0.61. Street is looking for $366 million and $0.80, respectively.
Still, with the shares down 23% since the start of the year, Englander must think they represent good value. He added DLB stock to his portfolio in the third quarter, buying 350,354 shares, now worth $25.5 million.
Enthusiastic sharing, 5-star analyst Tigers Ivan Feinseth The company is expected to overcome current difficulties and see great opportunities ahead.
“Short-term headwinds continue to create long-term buying opportunities as the continued integration of key DLB technologies in audio and video entertainment products grows and the production ecosystem grows. content, coupled with increased integration in entertainment production equipment and computing technology, will continue to drive growth,” Feinseth wrote.
“The arrival of Metaverse creates a new paradigm for audio and video integration. Metaverse will create an even more engaging and interactive environment, which will be enhanced by customizing content integration. more on an increasingly personalized basis,” added the analyst.
Accordingly, Feinseth recommends investors Buy and his $116 price target implies a one-year stock price gain of 59%. (To see Feinseth’s achievements, click here)
Overall, Wall Street tends to agree with the bulls. 4 recent analyst reviews consisting of 3 Buys and 1 Hold, giving a Strong Buy consensus rating and an average price target of $93.67 suggesting 28% upside potential over the stock price. It’s currently 73 dollars. (View DLB stock forecast on TipRanks)
Apellis Pharmaceuticals (APLS)
The final British endorsed name we will consider is Apellis Pharmaceuticals, a biopharmaceutical company whose mission is to discover and bring to market treatments for autoimmune and inflammatory diseases.
Started with the goal of being the first company to create targeted C3 therapy for disorders primarily controlled by complement – a feat many scientists say is difficult, if not impossible. doable – Apellis hit its target when the FDA approved Empaveli (pegcetacoplan) last year for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) last year. To date, this is the first and only targeted C3 therapy approved.
The company’s system boasts many different candidates in different stages of development that are dedicated to treating rare diseases, retina and neurological, but what is of interest here is the effort of The company aims to bring to market the first potential treatment for geographical atrophy (GA), a condition that can lead to blindness and affects more than five million people globally.
After the FDA approved the revised New Drug Application (NDA) for intravitreal pegcetacoplan, the company’s GA treatment, the PDUFA date has been set for February 26, 2023.
Englander most likely thinks its chances of success are pretty high, since he bought 257,869 shares of APLS – making the stock a new addition to his fund’s portfolio. These are now worth more than $12.6 million.
We can’t be sure if the drug is currently approved, but according to FDA comment, analyst Cowen Phil Nadeau quite confident in a positive outcome.
“The language in the FDA’s Standard Operating Procedures for Major Amendments suggests that review of unsolicited amendments is subject to FDA discretion, and new information is seen as ‘where revisions may be made. support approval during that review cycle’” wrote the 5-star analyst. “While it is impossible to know the FDA’s mind until PDUFA is available, it seems to us another data point where pegcetacoplan is well on its way to approval. Otherwise, the FDA would not have accepted the modification and renewal of the PDUFA, but instead, the CRL would have been issued on top of the original PDUFA.”
These comments reinforce Nadeau’s Good Performance (i.e. Buy) rating while his $70 price target suggests the stock is 42% undervalued. (To see Nadeau’s achievements, click here)
Overall, 12 analysts have given their views on APLS and these views are divided into 9 Buys and 3 Holds, providing the stock with a strong Buy consensus rating. At 76.17, the median target implies that the stock will deliver ~54% returns in the coming months. (View APLS stock forecast on TipRanks)
To find great ideas for trading stocks at attractive valuations, visit TipRanks’ Best stocks to buya newly launched tool that consolidates all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are those of the featured analyst only. Content is used for informational purposes only. It is very important that you do your own analysis before making any investment.
